Cargando…

Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression

Vaccine effectiveness (VE) and the urgency of booster vaccination against SARS-CoV-2 Omicron variant need evaluation. A systematic search was conducted from 1–6 April, 2022. VE difference (VED) estimates were assessed using random-effects and meta-regression analyses were performed for evaluating VE...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratama, Nando Reza, Wafa, Ifan Ali, Budi, David Setyo, Sutanto, Henry, Asmarawati, Tri Pudy, Barlian Effendi, Gema, Wungu, Citrawati Dyah Kencono
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783108/
https://www.ncbi.nlm.nih.gov/pubmed/36560590
http://dx.doi.org/10.3390/vaccines10122180
_version_ 1784857499615100928
author Pratama, Nando Reza
Wafa, Ifan Ali
Budi, David Setyo
Sutanto, Henry
Asmarawati, Tri Pudy
Barlian Effendi, Gema
Wungu, Citrawati Dyah Kencono
author_facet Pratama, Nando Reza
Wafa, Ifan Ali
Budi, David Setyo
Sutanto, Henry
Asmarawati, Tri Pudy
Barlian Effendi, Gema
Wungu, Citrawati Dyah Kencono
author_sort Pratama, Nando Reza
collection PubMed
description Vaccine effectiveness (VE) and the urgency of booster vaccination against SARS-CoV-2 Omicron variant need evaluation. A systematic search was conducted from 1–6 April, 2022. VE difference (VED) estimates were assessed using random-effects and meta-regression analyses were performed for evaluating VE over time. Compared to full dose, booster dose of overall vaccines provided better protection against any and severe Omicron infections within 3 months (p < 0.001), and within 3 months or more in any, severe, and symptomatic infections (p < 0.001). From meta-regression analysis of overall vaccines, the full-dose VE against any and symptomatic Omicron infections reduced per month by 2.45% and 5.5%, respectively; whereas booster dose effectiveness against any and symptomatic Omicron infections reduced per month by 1.79% and 1.14%, respectively. The VE estimates of booster dose provide excellent protection against symptomatic infection compared to full dose. The VE estimates of Ad26.COV2.S, BNT162b2, ChAdOx1 nCov-19, and mRNA-1273 against Omicron infection are generally moderate, despite the VE estimates declining over time.
format Online
Article
Text
id pubmed-9783108
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97831082022-12-24 Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression Pratama, Nando Reza Wafa, Ifan Ali Budi, David Setyo Sutanto, Henry Asmarawati, Tri Pudy Barlian Effendi, Gema Wungu, Citrawati Dyah Kencono Vaccines (Basel) Review Vaccine effectiveness (VE) and the urgency of booster vaccination against SARS-CoV-2 Omicron variant need evaluation. A systematic search was conducted from 1–6 April, 2022. VE difference (VED) estimates were assessed using random-effects and meta-regression analyses were performed for evaluating VE over time. Compared to full dose, booster dose of overall vaccines provided better protection against any and severe Omicron infections within 3 months (p < 0.001), and within 3 months or more in any, severe, and symptomatic infections (p < 0.001). From meta-regression analysis of overall vaccines, the full-dose VE against any and symptomatic Omicron infections reduced per month by 2.45% and 5.5%, respectively; whereas booster dose effectiveness against any and symptomatic Omicron infections reduced per month by 1.79% and 1.14%, respectively. The VE estimates of booster dose provide excellent protection against symptomatic infection compared to full dose. The VE estimates of Ad26.COV2.S, BNT162b2, ChAdOx1 nCov-19, and mRNA-1273 against Omicron infection are generally moderate, despite the VE estimates declining over time. MDPI 2022-12-19 /pmc/articles/PMC9783108/ /pubmed/36560590 http://dx.doi.org/10.3390/vaccines10122180 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pratama, Nando Reza
Wafa, Ifan Ali
Budi, David Setyo
Sutanto, Henry
Asmarawati, Tri Pudy
Barlian Effendi, Gema
Wungu, Citrawati Dyah Kencono
Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression
title Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression
title_full Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression
title_fullStr Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression
title_full_unstemmed Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression
title_short Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression
title_sort effectiveness of covid-19 vaccines against sars-cov-2 omicron variant (b.1.1.529): a systematic review with meta-analysis and meta-regression
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783108/
https://www.ncbi.nlm.nih.gov/pubmed/36560590
http://dx.doi.org/10.3390/vaccines10122180
work_keys_str_mv AT pratamanandoreza effectivenessofcovid19vaccinesagainstsarscov2omicronvariantb11529asystematicreviewwithmetaanalysisandmetaregression
AT wafaifanali effectivenessofcovid19vaccinesagainstsarscov2omicronvariantb11529asystematicreviewwithmetaanalysisandmetaregression
AT budidavidsetyo effectivenessofcovid19vaccinesagainstsarscov2omicronvariantb11529asystematicreviewwithmetaanalysisandmetaregression
AT sutantohenry effectivenessofcovid19vaccinesagainstsarscov2omicronvariantb11529asystematicreviewwithmetaanalysisandmetaregression
AT asmarawatitripudy effectivenessofcovid19vaccinesagainstsarscov2omicronvariantb11529asystematicreviewwithmetaanalysisandmetaregression
AT barlianeffendigema effectivenessofcovid19vaccinesagainstsarscov2omicronvariantb11529asystematicreviewwithmetaanalysisandmetaregression
AT wungucitrawatidyahkencono effectivenessofcovid19vaccinesagainstsarscov2omicronvariantb11529asystematicreviewwithmetaanalysisandmetaregression